-
Mashup Score: 11
James J. Harding, MD, discusses how the initial findings from CheckMate 9DW inform the role of nivolumab plus ipilimumab (NIVO + IPI) in the first-line (1L) treatment landscape for unresectable hepatocellular carcinoma (uHCC), considering factors such as efficacy, safety, and patient characteristics (eg, age) when selecting between first-line systemic immunotherapy (IO) regimens.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC: The CheckMate 9DW Study. - 19 day(s) ago
James J. Harding, MD, reviews the ongoing phase 3 CheckMate 9DW trial, which is investigating nivolumab plus ipilimumab (NIVO + IPI) vs lenvatinib or sorafenib as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC).
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: @HardingJJMD from @MSKCancerCenter reviews the ongoing phase 3 CheckMate 9DW trial, which is investigating nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma. #uHCC https://t.co/ZwDSM8zCBo
-
-
Mashup Score: 0STRIDE Regimen Exhibits Manageable Safety in Patients With uHCC - 2 year(s) ago
According to George Lau, MD, FRCP, FAASLD, patients with unresectable hepatocellular carcinoma who experienced immune-related adverse events with the STRIDE regimen were not precluded from receiving survival benefit.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#STRIDE in patients with #uHCC showed manageable and low-grade immune-related adverse events, according to findings from the phase 3 HIMALAYA trial presented at #ASCO2023. #lcsm | @ASCO https://t.co/5cIJK9Msue
-
-
Mashup Score: 0
Phase 3 results from the combination of rivoceranib and camrelizumab have excited investigators enough to seek FDA approval for patients with unresectable hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A new drug application seeking approval of rivoceranib + camrelizumab for unresectable hepatocellular carcinoma has been submitted to the #FDA. #uHCC https://t.co/R72hz2SkGq
-
-
Mashup Score: 5Ghassan Abou-Alfa, MD @GABOUALFA @Sloan_Kettering #ASCO - 3 year(s) ago
Ghassan Khaled Abou-Alfa, MD, MBA, Medical Oncologist, Attending Physician at Memorial Sloan Kettering Cancer Center. In this video, he speaks about the AS
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Phase III HIMALAYA Trial Of uHCC Ghassan Abou-Alfa, MD @GABOUALFA @Sloan_Kettering #ASCOGI22 #GI22 #uHCC #Research https://t.co/DmRAVqFsmB https://t.co/ffYDBmNm0O
-
-
Mashup Score: 4Podcast Ghassan Abou-Alfa, MD @GABOUALFA @Sloan_Ketteri - 3 year(s) ago
Ghassan Khaled Abou-Alfa, MD, MBA, Medical Oncologist, Attending Physician at Memorial Sloan Kettering Cancer Center. In this video, he speaks about the AS
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Podcast - Phase III HIMALAYA Trial Of uHCC Ghassan Abou-Alfa, MD @GABOUALFA @Sloan_Kettering #ASCOGI22 #GI22 #uHCC #Research Link to Audio: https://t.co/SjziNunXje https://t.co/JjHu4ddSeF
-
-
Mashup Score: 0Clinical Edge Journal Scan Commentary: HCC January 2022 - 3 year(s) ago
Several novel options for the treatment of unresectable hepatocellular carcinoma (uHCC) have been evaluated over the past few years. This month, we will review recently published articles that address systemic therapies for uHCC. For many years, sorafenib was the only FDA-approved systemic treatment for patients with uHCC. Initial case reports of remarkable responses…
Source: www.mdedge.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A rundown on new research on systemic therapies for #uHCC. https://t.co/sEvjUzsWdc https://t.co/XlLSyxxzn0
-
WATCH: James J. Harding, MD, (@HardingJJMD) discusses how the initial findings from CheckMate 9DW inform the role of nivolumab + ipilimumab in the first-line treatment landscape for unresectable hepatocellular carcinoma #uHCC. @MSKCancerCenter https://t.co/15XaMKCF3Y